Latest Period
Q2 2026
Security Snapshot
Liminatus Pharma, Inc. - Common Stock , par value $0.0001 per share (LIMN) Institutional Ownership
CUSIP: 53271X108
13F Institutional Holders and Ownership History from Q2 2025 to Q2 2026
Institutions Reporting
13
Shares (Excl. Options)
616,622
Price
$0.11
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock , par value $0.0001 per share
- Symbol
- LIMN on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 616,622
- Total 13F value
- $69,097
- Portfolio coverage rank
- 0%
- Share change
- -508,816
- Value change
- -$63,243
- Number of holders
- 13
- Shares outstanding
- 67,187,216
- SEC-reported price per share
- $0.10
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- LIMN - Liminatus Pharma, Inc. - Common Stock , par value $0.0001 per share is tracked under CUSIP 53271X108.
- 13 institutions reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 15 to 13 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $253,756 to $69,097.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 13 institutions filings for Q2 2026.
Security key
53271X108
Latest holder period
Q2 2026
13F holders
13
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
LIMN full holder history
Liminatus Pharma, Inc. SEC filings
Liminatus Pharma, Inc. company facts
Liminatus Pharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 53271X108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
LIMN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Valetudo Therapeutics LLC | 14% | -39% | $1,346,514 | +$482,797 | 9,617,954 | +56% | Valetudo Therapeutics LLC | 02 Jul 2026 |
| Iris Acquisition Holdings LLC | 26% | 6,900,000 | Iris Acquisition Holdings LLC | 30 Apr 2025 | ||||
| Ewon Comfortech Co., Ltd. | 11% | +85% | $770,000 | +$560,000 | 5,500,000 | +267% | Ewon Comfortech Co., Ltd. | 24 Jun 2026 |
| KH Feelux Co., Ltd | 15% | $20,880,000 | 4,000,000 | KH Feelux Co., Ltd | 30 Apr 2025 | |||
| Samda Biolab Co., Ltd. | 5.1% | $376,920 | 3,426,548 | Samda Biolab Co., Ltd. | 02 Jul 2026 | |||
| INTRACOASTAL CAPITAL, LLC | 5% | $1,487,437 | 2,065,885 | Mitchell P. Kopin | 17 Feb 2026 | |||
| Red Peony Association 1st | 5.7% | $7,673,400 | 1,470,000 | Red Peony Association 1st | 30 Apr 2025 | |||
| Nongae Apple Association 1st | 5.7% | $7,673,400 | 1,470,000 | Nongae Apple Association 1st | 30 Apr 2025 |
As of 30 Jun 2026, 13 institutional investors reported holding 616,622 shares of Liminatus Pharma, Inc. - Common Stock , par value $0.0001 per share (LIMN). This represents 0.92% of the company’s total 67,187,216 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Latest
Q2 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 616,622 | $69,097 | -$63,243 | $0.11 | 13 |
| 2026 Q1 | 1,475,438 | $253,756 | +$182,580 | $0.17 | 15 |
| 2025 Q4 | 317,192 | $193,497 | -$19,326 | $0.61 | 11 |
| 2025 Q3 | 261,924 | $437,442 | +$66,142 | $1.67 | 10 |
| 2025 Q2 | 204,702 | $2,282,195 | +$2,282,195 | $11.15 | 10 |